Prof.G.Walter Canonica
Allergy and Respiratory Diseases Clinic
DIMI-‐University of Genoa
Italy
Presidente Congreso SLaai 2015: Dr. Alfonso Cepeda Sarabia
Call Girls Ahmedabad Just Call 9630942363 Top Class Call Girl Service Available
The Future of Allergy and Clinical Immunology Prof. G. Walter Canonica - Congreso Slaai 2015
1.
2. Prof.
Giorgio
Walter
Canonica
Allergy
and
Respiratory
Diseases
Clinic
DIMI-‐University
of
Genoa
IRCCS
AOU
San
Mar:no-‐Genova
Italy
President
President
SLAAI, March 15, 2015
The Future of Allergy
and
Clinical Immunology
39. The promise of personalized medicine
• More effective medicines
• Safer medicines
• Cheaper medicines
• Better healthcare
• Cheaper healthcare
• Less (rather than more)
healthcare disparity
42. G551D
is
the
third
most
common
muta:on,
affec@ng
~4%
of
pa@ents.
For
pa:ents
homozygous
for
Δ508,
Vertex
has
another
drug,
VX-‐809,
which
acts
by
increasing
the
transport
of
CFTR
protein
to
the
cell
surface.
A
phase
2
clinical
trial
of
combined
VX-‐809
and
VX-‐770
treatment
in
Δ508
pa:ents
is
in
progress.
Vx-‐770
poten:ates
CFTR
func:on
by
promo:ng
decoupling
between
the
ga:ng
cycle
and
ATP
hydrolysis
cycle.
Jih
KY.
et
al.
PNAS.
2013;
110:
4404-‐9
Vx-‐770;
Ivaca[or
A CFTR potentiator in patients with cystic fibrosis and
the G551D mutation (most
prevalent
ga:ng
muta:on)
Ramsey BW, et al. N Engl J Med. 2011; 3658: 1663-72
Complex disease will be stratified into a series of
pathway specific disorders creating opportunities for
both companion diagnostics and targeted
prevention and treatments.
But also a new Taxonomy of disease based upon causative
pathways rather than signs and symptoms.
43. Crea:on
of
a
New
Taxonomy
first
requires
an
“Informa:on
Commons”
in
which
data
on
large
popula:ons
of
pa:ents
become
broadly
available
for
research
use
and
a
“Knowledge
Network”
that
adds
value
to
these
data
by
highligh:ng
their
inter-‐
connectedness
and
integra:ng
them
with
evolving
knowledge
of
fundamental
biological
processes
Toward
Precision
Medicine.
US
Nat
Acad
Sci
2011
Reclassification of human disease by
identifiable causal pathways
50. ASTHMA HORIZON PLANNING
in the next 5 years
tralokinumab
(an@
IL
13,
MedImmune)
ligelizumab
(an@
IgE,
Novar@s)
dupilumab
(an@
IL
4
rec,Sanofi
Regeron)
55. JACI
2013
ISSN 0091-6749
V O L U M E 1 2 9 N O. 4
A P R I L 2 0 1 2
www.jacionline.org
THE JOURNAL OF
AllergyAND Clinical
Immunology
CURRENT PERSPECTIVES
ICON: Food allergy
The role of dendritic cells in food allergy
ROSTRUM
Multiple-allergen and single-allergen
immunotherapy strategies in polysensitized
patients: Looking at the published evidence
Health literacy and asthma
WORKSHOP SUMMARY
Understanding the complexity of IgE-related
phenotypes from childhood to young
adulthood: A Mechanisms of the Development
of Allergy (MeDALL) Seminar
CLINICAL REVIEWS
An update on the role of human dendritic cells
in patients with atopic dermatitis
MECHANISMS OF ALLERGIC DISEASES
The role of dendritic cells in asthma
EDITORIALS
We call for iCAALL: International Collaboration
in Asthma, Allergy and Immunology
The airway epithelium in childhood asthma
TH
9 cells: In front and beyond TH
2
Nonimmediate drug allergy: Diagnostic benefit
of skin testing and practical approach
OFFICIAL JOURNAL OF
67. Auffray
et
al.
Genome
Med
2009;1:2
PaEent
reported
Clinical
FuncEonal
Cellular
Molecular
Future
of
phenotyping:
‘Systems
Medicine’
68. Prof.
Giorgio
Walter
Canonica
Allergy
and
Respiratory
Diseases
Clinic
DIMI-‐University
of
Genoa
IRCCS
AOU
San
Mar:no-‐Genova
Italy
President
President
SLAAI, March 15, 2015
The Future of Allergy
and
Clinical Immunology
(Part IV - final)
81. 0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
t=p/4
x
arithme2c
mean
of
orthogonal
intercepts
PRE
POST
RESULTS
Riccio,
Dal
Negro
et
al.,Int.J.Immunopathol.
&
Pharmacol.2012
82. 3.00
5.50
8.00
10.50
13.00
BEFORE
AFTER
TREATMENT
t=p/4
x
arithme2c
mean
of
ortogonal
intercept
12 month Xolair treatment
RESULTS
Riccio,
Dal
Negro
et
al.,Int.J.Immunopathol.
&
Pharmacol.2012
RESPONDER
NON
RESPONDER
6.25 µ
Severe
Asthma
Cut
off
95. FINAL
MESSAGE
Bioinforma2cs,
E-‐health
records,
Bio-‐banks
and
data
protec2on
Although
‘omics’
datasets
have
provided
remarkable
insights,
it
is
by
analysing,
linking
and
comparing
different
large
datasets
(genomic,
clinical
outcomes,
imaging
etc.)
that
the
greatest
insights
have
been
gained
–
so-‐
called
‘big
data’.
96. XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología 2015
Presidente: Alfonso Mario Cepeda Sarabia
Comité Organizador Local: Edgardo Jares, Anahí Yañez, Estrella Asayag
Presidentes Sociedad Latinoamericana de Alergia, Asma e Inmunología, Slaai:
2013-2015: Alfonso Mario Cepeda Sarabia - 2015-2017: Juan Carlos Sisul Alvariza
Buenos Aires, marzo 14-16, 2015
http://www.slaai2015.com/comites-del-congreso/
Información Slaai: www.slaai.org
Programa Congreso Para Todos
Conferencias XVIII Congreso Latinoamericano de Alergia, Asma e Inmunología
Sociedad Latinoamericana de Alergia, Asma e Inmunología, SLaai